Latest News-Ascletis Pharma Inc. Mediaroom_Page

Ascletis Announces China IND Approval of Its Second FASN Inhibitor ASC60 for Treatment of Advanced Solid Tumors

HANGZHOU, China and SHAOXING, China, April 6, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2022-04-06 17:10 2197

Ascletis Announces Completion of First Sale of Its Ritonavir Tablets in Zhejiang Province

HANGZHOU, China and SHAOXING, China, April 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2022-04-04 17:10 2489

Ascletis Announces Submission of Marketing Authorization Application for Ritonavir in Hong Kong

HANGZHOU and SHAOXING, China, April 3, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today...

2022-04-03 18:20 3284

Ascletis Announces Completion of Patient Enrollment in Phase II Clinical Trial of ASC42, an In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

--Compared to the placebo cohort, both 10 mg and 15 mg ASC42 cohorts are safe and well tolerated to...

2022-03-30 18:26 1748

Ascletis Announces the Latest Results of the Preclinical Studies of Two Novel Anti-Cancer Drug Candidates, ASC61 and ASC60, to be presented at AACR Annual Meeting 2022

HANGZHOU, China and SHAOXING, China, March 27, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672...

2022-03-27 18:30 3146

Business Update on ASC10, an Oral Double Prodrug against COVID-19

HANGZHOU and SHAOXING, China, March 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) toda...

2022-03-15 19:55 2113

Ascletis Announces Further Expansion of Ritonavir Oral Tablet Production Capacity to 530 Million Tablets Per Year

HANGZHOU, China and SHAOXING, China, March 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis,...

2022-03-13 18:30 2902

Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries

-- Ritonavir marketing authorization applications have been submitted to Spain, Portugal, Italy, Be...

2022-03-01 17:30 2273

Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients

HANGZHOU, China and SHAOXING, China, Feb. 14, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2022-02-14 17:34 2866

Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries

HANGZHOU, China and SHAOXING, China, Feb. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2022-02-13 18:30 3310

Ascletis Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant

* ASC10-A demonstrated strong in vitro antiviral activity against multiple SARS-CoV-2 virus varia...

2022-02-07 19:00 2358

Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

* The objectives of the U.S. Phase I trial are to find a recommended Phase II dose and obtain pre...

2022-02-06 18:30 3292

Ascletis Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA

HANGZHOU, China and SHAOXING, China, Jan. 26, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2022-01-26 19:00 2934

Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2022-01-23 18:35 3414

Ascletis Announces Signing of Ritonavir Tablet Purchase Agreement with Phokam Pharmaceutical Import-Export Co., Ltd of Laos

HANGZHOU and SHAOXING, China, Jan. 18, 2022 /PRNewswire/ -- Ascletis Pharma Inc. ("Ascletis") (HKEX...

2022-01-18 18:00 2294

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

-- Estimated 1.59 million chronic hepatitis B (CHB) patients in the U.S. -- Interim results of the ...

2022-01-17 18:12 3474

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne

HANGZHOU and SHAOXING, China, Jan. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today...

2022-01-13 17:30 3139

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

HANGZHOU, China and SHAOXING, China, Jan. 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2022-01-11 08:30 2497

Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

HANGZHOU, China and SHAOXING, China, Jan. 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2022-01-10 08:30 2916

Gannex Announces Completion of the U.S. Phase I Trial of ASC43F, an In-House Developed First-in-Class Dual Targeting Fixed-dose Combination Tablet for NASH

* ASC43F was safe and well tolerated in healthy subjects with no clinically significant study dru...

2022-01-04 08:30 2817